Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim that Enbrel is associated with serious infections and malignancies is directly supported by the provided label text (Sections 5.1 Serious Infections and 5.3 Malignancies) with no contradictions.
Category Scores
Accurate Statements
SERIOUS INFECTIONS
Supported by label Section 5.1 Serious Infections: increased risk for serious infections; discontinue if serious infection or sepsis; includes examples such as active TB and invasive fungal infections.
MALIGNANCIES
Supported by label Section 5.3 Malignancies: lymphoma and other malignancies, some fatal, reported in children and adolescent patients treated with TNF-blockers including Enbrel.
Unsupported Statements
Contradictions
Important Omissions
The claim is broad ('SERIOUS INFECTIONS and MALIGNANCIES') and does not include label details such as specific infection types (e.g., histoplasmosis, coccidioidomycosis) or the instruction to test for latent TB before and during therapy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are consistent with label warnings and do not introduce conflicting or unsupported safety assertions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of some specific label details (e.g., TB testing and examples of infection types) that are present in the warning sections.
Suggested Improvement
If expanding beyond the broad claim, include key label specifics from Sections 5.1 and 5.3 (e.g., TB screening/testing guidance and example infections/malignancies mentioned in the label).